Drugs / Refresh Optive MEGA-3
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06975891 | May → Sep 2025 | dry eye syndrome | Scripps Poway Eyecare and Optometry | Terminated | No outcome recorded |
| Phase 4 | NCT03380624 | Mar 2017 → Jun 2018 | dry eye syndrome | Ohio State University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Refresh Optive MEGA-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03380624 ↗ |
| Modality | Other / unclassified | “two US Monograph lubricant eyedrop formulations” NCT03380624 ↗ |
| Route | Other | “one drop of Refresh Optive MEGA-3 before taking lipid layer thickness measurements” NCT03380624 ↗ |